Aileron Therapeutics was a clinical-stage biopharmaceutical company that historically focused on developing and advancing a proprietary platform of 'stapled' alpha-helical peptides. These were designed to mimic the structures of natural proteins to modulate cellular pathways, primarily aimed at treating cancer and other serious diseases. Their lead drug candidate was ALRN-6924, which targeted the p53 tumor suppressor pathway. In late 2023, Aileron Therapeutics entered into a merger agreement with Lung Therapeutics, Inc., and the combined entity subsequently merged with Longeveron Inc. in early 2024, ceasing operations under the Aileron Therapeutics name.
The Cambridge headquarters served as the command center for Aileron's corporate strategy, clinical development programs, research initiatives, and administrative operations.
Located within a multi-tenant building in a key biotech cluster, the facility would have included modern office spaces designed to support executive, clinical, and administrative functions. Specific architectural highlights of their leased space are not publicly detailed.
The work culture at Aileron Therapeutics, typical of a clinical-stage biotech, likely fostered innovation, scientific excellence, a strong sense of urgency, and collaboration, driven by the goal of addressing unmet medical needs for patients.
Its Cambridge location provided Aileron with strategic advantages, including proximity to leading academic institutions, a rich talent pool, and a vibrant ecosystem of research organizations and potential partners.
As a U.S.-based company, Aileron Therapeutics's global functions were primarily related to the execution of its clinical trials, which often involve international sites and collaborations with research institutions or contract research organizations (CROs) in various countries to access diverse patient populations and expertise.
840 Memorial Drive, Third Floor
Cambridge
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Aileron Therapeutics' leadership includes:
Aileron Therapeutics has been backed by several prominent investors over the years, including:
In the 12 months leading up to its merger announcements, Aileron Therapeutics had a key executive appointment. The subsequent merger process led to the transition of its executive team as the company integrated into new entities.
Discover the tools Aileron Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Historically, Aileron Therapeutics used common corporate email formats. The primary domain associated with the company was aileronrx.com. Given the company's merger and cessation of operations under this name, these email addresses are no longer active.
Aileron Therapeutics likely used formats such as [first_initial][last]@aileronrx.com or [first].[last]@aileronrx.com
Format
jdoe@aileronrx.com
Example
0%
Success rate
GlobeNewswire • October 24, 2023
Aileron Therapeutics, Inc. and Lung Therapeutics, Inc. announced they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The merged company planned to focus on advancing Lung Therapeutics' pipeline for rare lung diseases....more
GlobeNewswire • June 5, 2023
Aileron Therapeutics announced it would effect a 1-for-20 reverse stock split of its common stock, effective June 6, 2023, to regain compliance with Nasdaq's minimum bid price requirement....more
GlobeNewswire • March 27, 2023
Aileron Therapeutics announced the appointment of Susan M. Dube, CPA, as its Chief Financial Officer and Secretary. Ms. Dube brought over 20 years of finance and accounting experience in the life sciences industry to the role....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Aileron Therapeutics, are just a search away.